Back to top

Veraxa Biotech advances VXA-222 following milestone in OmniAb pact

Veraxa Biotech (VRXA) announced the advancement of bispecific ADC program VXA-222, following successful achievement of a key technical milestone in...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

OmniAb, Inc. (OABI)